CytoDyn (CYDY) Accumulated Expenses (2011 - 2026)
CytoDyn's (CYDY) quarterly Accumulated Expenses came in at $11.8 million in Q1 2026, up 5145.54% YoY from $224000.0 in Q1 2025, and down 28.79% on a QoQ basis from $16.5 million in Q4 2025.
CytoDyn (CYDY) Accumulated Expenses (2011 - 2026) Analysis & Trends
CytoDyn (CYDY) has 15 years of Accumulated Expenses data on file, last reported at $11.8 million in Q1 2026.
- Quarterly Accumulated Expenses rose 5145.54% year-over-year to $11.8 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $11.8 million (up 5145.54% YoY) and the FY2025 annual result came in at $18.2 million, up 8626.44% from the prior year.
- Accumulated Expenses fell to $11.8 million in Q1 2026, from $16.5 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $18.2 million in Q2 2025 to a low of $111000.0 in Q4 2024.
- A 5-year average of $4.0 million and a median of $496000.0 in 2022 frame the typical range for Accumulated Expenses.
- The widest YoY moves for Accumulated Expenses: up 14764.86% in 2025, down 98.41% in 2025.
- Tracing CYDY's Accumulated Expenses over 5 years: stood at $496000.0 in 2022, then plunged by 54.03% to $228000.0 in 2023, then sank by 51.32% to $111000.0 in 2024, then jumped by 14764.86% to $16.5 million in 2025, then slipped by 28.79% to $11.8 million in 2026.
- The last three Accumulated Expenses figures came in at $11.8 million (Q1 2026), $16.5 million (Q4 2025), and $236000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | CytoDyn | 258.01 Mn | 258.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 11.75 Mn |
| Nov 30, 2025 | 16.50 Mn |
| Aug 31, 2025 | 236,000.00 |
| May 31, 2025 | 18.15 Mn |
| Feb 28, 2025 | 224,000.00 |
| Nov 30, 2024 | 111,000.00 |
| Aug 31, 2024 | 362,000.00 |
| May 31, 2024 | 208,000.00 |
| Feb 29, 2024 | 14.08 Mn |
| Nov 30, 2023 | 228,000.00 |
| Aug 31, 2023 | 239,000.00 |
| May 31, 2023 | 168,000.00 |
| Feb 28, 2023 | 1.21 Mn |
| Nov 30, 2022 | 496,000.00 |
| Aug 31, 2022 | 792,000.00 |
| May 31, 2022 | 2.01 Mn |
| Feb 28, 2022 | 1.64 Mn |
| Nov 30, 2021 | 796,000.00 |
| Aug 31, 2021 | 2.24 Mn |
| May 31, 2021 | 11.01 Mn |